Use of dr-18 and oncolytic vaccinia virus in preparation of anti-tumor drug
AssigneeGuangzhou Virotech Pharmaceutical Co., Ltd.
InventorsZiqing LIN, Guang'en WU, Songmin HE, Yichun LIU, Shoufang GONG
Life of this patent
Estimating the term…
Abstract
The present disclosure belongs to the field of biological medicines, and relates to use of DR-18 and an oncolytic vaccinia virus in the preparation of an anti-tumor drug. The present disclosure has found for the first time that combined use of the oncolytic vaccinia virus and DR-18 has a synergistic anti-tumor effect. The present disclosure also relates to an anti-tumor pharmaceutical composition comprising an oncolytic vaccinia virus and DR-18, and use of an oncolytic vaccinia virus and DR-18 in the preparation of an anti-tumor drug.
Claims21
1-15. (canceled)
A pharmaceutical combination comprising:
- DR-18, and
- an oncolytic vaccinia virus.
A recombinant oncolytic vaccinia virus, wherein a genome of the recombinant oncolytic vaccinia virus comprises:
- a mutated oncolytic vaccinia virus nucleotide sequence, and
- a DR-18 nucleotide sequence.
Dependencies are inferred from the claim text.